Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272

Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272

US Patent 10729672 · Granted Aug 4, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method for treating gefitinib resistant cancer2020
Method for treating gefitinib resistant cancer2020
Antineoplastic combinations containing HKI-272 and vinorelbine2018
Antineoplastic combinations containing HKI-272 and vinorelbine2016
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine2016
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine2014
Cut-point in PTEN protein expression that accurately identifies tumors and is pr2012
Protein tyrosine kinase enzyme inhibitors2011
Protein tyrosine kinase enzyme inhibitors2008
Treatment of neoplasms with CCI-779/EKB-569 combination2008
Reversal of multidrug resistance in human colon carcinoma cells2005
Antineoplastic combinations comprising2003